Cargando…
A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas
Background: Meningiomas are the most common adult primary intracranial tumors in the United States. Despite high recurrence rate of atypical and malignant subtypes, there is no approved drug indicated specifically for meningioma. Since the majority of meningiomas exhibit high density of somatostatin...
Autores principales: | Hrachova, Maya, Nguyen, Emely Nhi T., Fu, Beverly D., Dandekar, Manisha J., Kong, Xiao-Tang, Cadena, Gilbert, Hsu, Frank P. K., Billimek, John, Taylor, Thomas H., Bota, Daniela A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218113/ https://www.ncbi.nlm.nih.gov/pubmed/32435228 http://dx.doi.org/10.3389/fneur.2020.00373 |
Ejemplares similares
-
Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide
por: Petersen, Holger, et al.
Publicado: (2011) -
Sandostatin therapy in patients with chronic sarcoidosis
por: Timmermans, Wilhelmina M.C., et al.
Publicado: (2017) -
SAT-432 MTD201 Has a Favourable 28-Day Sustained Release Profile Compared to Sandostatin LAR in Healthy Subjects
por: Seaman, Paul, et al.
Publicado: (2019) -
NCMP-19. SIDE EFFECTS FROM CHEMOTHERAPY VERSUS SYMPTOMS FROM COVID-19 INFECTION
por: Du, Senxi, et al.
Publicado: (2020) -
Somatic SMARCB1 Mutation in Sporadic Multiple Meningiomas: Case Report
por: Wang, Alice S., et al.
Publicado: (2018)